Registration filing
Logotype for Abeona Therapeutics Inc

Abeona Therapeutics (ABEO) Registration filing summary

Event summary combining transcript, slides, and related documents.

Logotype for Abeona Therapeutics Inc

Registration filing summary

18 Nov, 2026

Company overview and business model

  • Commercial-stage biopharma developing therapies for rare and serious diseases; portfolio includes ZEVASKYN for recessive dystrophic epidermolysis bullosa, ABO-801 for eosinophilic esophagitis (EoE), and investigational T-cell therapy ABO-701.

  • ZEVASKYN is manufactured in Cleveland and delivered through qualified treatment centers; eight centers were active as of November 2026, with expansion discussions underway.

  • ABO-801 is a Phase 3-ready, once-daily oral disintegrating fluticasone tablet acquired from Ellodi Pharmaceuticals on November 6, 2026.

Use of proceeds and capital allocation

  • No proceeds from registered resales will go to the issuer; selling stockholders receive sale proceeds, and issuer-paid registration costs include filing, Nasdaq, legal, and audit fees.

  • The November 2026 private placement generated approximately $30 million gross; cash exercise of all registered pre-funded warrants would yield approximately $160, with no proceeds from cashless exercise.

Risk factors and disclosures

  • Investment carries a high degree of risk; forward-looking outcomes include ZEVASKYN commercialization, ABO-801 integration and development, clinical progress and approvals, financing needs, equity dilution, and IP protection.

  • Forward-looking statements are subject to risks, uncertainties, and assumptions; actual results may differ materially, and statements speak only as of their respective dates.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Abeona Therapeutics